ERBB2 and breast cancer: Two NCI cooperative group trials, NSABP B-31 and NCCTG N9831, showed that amongst 3752 women with HER2-overexpressing breast cancer who received adjuvant chemotherapy, and radio- or endocrine therapy as appropriate, those who also received trastuzumab were significantly less likely to have disease progression.